Metagenomic Sequencing Market Size, Key Companies, Company Product Portfolio, Hospital Procurement Trends, Manufacturing Capacity, Sales Performance, Regulatory Approvals, Company Market Share, and Forecast

Revenue, 2025

USD 3.66 Bn

Forecast Year, 2035

USD 19.08 Bn

CAGR, 2026 - 2035

17.95%

Report Coverage

Global

What is the Metagenomic Sequencing Market Size?

The global metagenomic sequencing market size is calculated at USD 3.66 billion in 2025 and is predicted to increase from USD 4.35 billion in 2026 to approximately USD 19.08 billion by 2035, expanding at a CAGR of 17.95% from 2026 to 2035. The metagenomic sequencing market is driven by rising infectious diseases and antimicrobial resistance, rapid adoption of precision medicine and increasing investment in healthcare.

Market Highlights

• North America region dominated the market and recorded more than 42.14% of the revenue share in 2025.
• The services segment dominated the market in 2023, growing at a CAGR of 17.90% between 2026 and 2035.
• The drug discovery segment dominated the market in 2024 progressing with a CAGR of 18.59% between 2026 and 2035.

Market Size and Forecast

• Market Size in 2025: USD 3.66 Billion
• Market Size in 2026: USD 4.35 Billion
• Forecasted Market Size by 2035: USD 19.08 Billion
• CAGR (2026-2035): 17.95%
• Largest Market in 2025: North America
• Fastest Growing Market: Asia Pacific

Market Overview

The metagenomic sequencing market covers technologies and services used to study the combined genetic material of microorganisms present in a biological or environmental sample. Unlike conventional methods that examine one cultured organism at a time, metagenomic sequencing analyses DNA from an entire microbial community, including bacteria, viruses, and fungi, without prior culturing. The market includes sequencing platforms, sample preparation kits, reagents, bioinformatics software and sequencing services. The market is growing due to increasing prevalence of genetic and infectious disorders and growing research and development activities.

What is Metagenomic Sequencing?

Metagenomic sequencing is the collective analysis of all genomic material present in a sample, thus eliminating the need to isolate and cultivate individual organisms. It uses next generation sequencing to quickly analyze microbial community diversity and understand the roles of constituent species. As uncultivability and genomic diversity serve as the two major obstacles in the advancement of environmental and clinical microbiology, metagenomic sequencing has gained immense traction among healthcare professionals and researchers.

How is AI Transforming Metagenomic Sequencing?

AI transforms metagenomic sequencing by improving efficiency and accuracy. AI and machine learning algorithms can enable novel pathogen detection and sequence classification. They can predict disease outcomes and infectious disease outbreaks in a population by analyzing vast amounts of data. AI and ML can find unknown pathogens based on a patient's unique microbiome. The AI-based systems provide an advantage in the fast, accurate, and efficient evaluation and characterization of microbial datasets.

AI transforms metagenomic sequencing by improving efficiency and accuracy. AI and machine learning algorithms can enable novel pathogen detection and sequence classification. They can predict disease outcomes and infectious disease outbreaks in a population by analyzing vast amounts of data. AI and ML can find unknown pathogens based on a patient's unique microbiome. The AI-based systems provide an advantage in the fast, accurate, and efficient evaluation and characterization of microbial datasets.

Metagenomic Sequencing Market Growth Factors

The ability of scientists to study microbial communities from an infinite variety of environments is expanding, and one of the main factors promoting this growth is the continuous development of faster sequencing techniques, rising demand for personalized medicine, technological advancements, and rising funding for genomic research. Advancements in sequencing technologies and data analysis tools have made metagenomic sequencing more accessible and affordable, which is expected to drive market growth.

Molecular biology study has been accelerated by the development of Next Generation DNA Sequencing (NGS) technology, leading to a wealth of new findings and ideas. Rising technical developments in DNA sequencing will therefore probably fuel market expansion over the course of the projection period. Increasing government initiatives and financing for large-scale sequencing projects, as well as rising general knowledge of genetic abnormalities, are some of the main forces propelling the global metagenomic sequencing market. Numerous hereditary diseases with distinct clinical symptoms have been discovered. A confirmed birth abnormality affects 3 to 6% of infants, at least 50% of whom have a genetic basis. Around 30% of postnatal infant mortality in wealthy countries is attributable to genetic illness; 30% of juvenile hospital hospitalizations and 10% of adult hospital admissions have a genetic cause.

The growing adoption of next-generation sequencing (NGS) technologies is also expected to drive the growth of the market. The development of novel sequencing platforms with improved accuracy, throughput, and cost-effectiveness has increased the adoption of NGS technologies for metagenomic sequencing. Additionally, the increasing demand for metagenomic sequencing in environmental monitoring and microbiome research is expected to drive the growth of the market. Over a quarter of NHGRI's FY2018 funding is allocated to projects with substantial computational genomics or data science components; these fields are essential to many of NHGRI's awards and initiatives. The NHGRI Funding Policy's general concepts and objectives are followed by funding for computational genomics and data science.

Some of the key trends in the metagenomic sequencing market are:

• Metagenomics has important uses in many different areas.
• Progress in metagenomics sequencing technology.
• A variety of programs and financial support from public and private organizations for extensive sequencing efforts.
• Use of machine learning and AI in analyzing metagenomic data.

Market Outlook

• Industry growth overview - The metagenomic sequencing market is expected to expand rapidly as sequencing costs decline and applications are increasing across microbiome research and infectious disease.
• Global expansion - North America remains a leading market, while Asia Pacific is creating strong opportunities in market expansion due to expanding research infrastructure and rising adoption of sequencing technologies in healthcare.
• Major Investors - Pharmaceutical and healthcare companies are increasing their investment in the market. Major investors in the market include BlackRock, The Vanguard Group, Fidelity Investments, ARK Investment Management, Deerfield Management, Casdin Capital, Orbimed Advisors, Arch Venture Partners, and Flagship Pioneering.
• Startup ecosystem - The startup ecosystem is entering the market through microbiome diagnostics, AI based data interpretation and therapeutic discovery.

Market Scope

Market Dynamics

Drivers

NGS platform technology is constantly evolving

The development of effective, portable, and simple-to-use NGS systems with better turnaround rates has been made possible by the ongoing technological advancements in sequencers. A number of well-known businesses are increasingly concentrating on R&D in order to improve their marketplaces and share as a result of the launch of such goods and technologies giving competitors an instant competitive advantage.

For instance, the Sequel ll System was introduced by Pacific Biosciences of California, Inc. (US) in April 2019. When compared to the prior Sequel System, the new product lowers project costs and timelines by roughly eight times the amount of data production. PromethlON 24 and Prometh|ON 48 were introduced by Oxford Nanopore Technologies plc. (UK) in January 2019. These devices provide modular high throughput, extended read, and direct nanopore sequencing data. Thermo Fisher Scientific's lon GeneStudio S5 System and Illumina's Seq 100 are two other ground-breaking systems that guarantee high sequencing efficiency at lower prices.

Challenges

Budgetary restrictions for consumers in emerging nations

Academic R&D in emerging nations is primarily reliant on outside financing. Despite ongoing attempts by governments and private organizations to provide funding for research globally, many study and academic institutions experience financial restrictions when it comes to the acquisition and use of cutting-edge and expensive equipment and technologies. NGS sequencers are still expensive even though NGS sequencing costs have decreased. The NovaSeq 5000 and 6000, lumina's most sophisticated sequencing systems, cost USD 850,000 and USD 985,000, respectively. These sequencers are approximately 70% quicker at sequencing than the majority of llumina's current platforms, and they can be made even faster with future system and program updates. Another major participant in the NGS market, Pacific Biosciences of California, offers its PacBio RS Il at USD 750,000 and its most recent sequencing platform, the Sequel system, at USD 350,000. Even though low-cost sequencing systems like the iSeq have entered the market, many end consumers in developing APAC and LATAM nations still find their price to be prohibitive. As a consequence, the adoption of related NGS products for metagenomics is being hampered by the restricted use of cutting-edge technologies, such as NGS, in university and research institutions in emerging nations.

Opportunities

NGS data analysis using big data

The amount of data generated during whole-genome sequencing typically ranges in the terabyte region. The management of such massive amounts of data is a significant worry for NGS-based metagenomic sequencing's end users. Due to inconsistent data formats and a dearth of industry-wide standardization for data output from various NGS systems, data storage needs can be quite complicated. However, the output of NGS runs has grown considerably as a result of the use of big data tools, Al, and process management. With improvements in sequencing technology, more data is generated during a sequencing cycle. In comparison to 16.2 megabytes at the beginning of the Human Genome Project in 2001, one human genome's sequencing results in approximately 743 terabytes (743,000 gigabytes) of data as of July 2017, according to a study from the National Human Genome Research Institute. Because the volume of produced genetic data exceeds the capabilities of human analysis, there is a chance to use cutting-edge computing techniques for evaluation and analysis. Various businesses are integrating cutting-edge algorithmic technologies into their sequencing products in line with this. For example,

• Illumina (US) introduced Illumina Connected Analytics (ICA), a fresh and comprehensive analytics system, in January 2021. examine and investigate vast amounts of multi-omics data
• In 2020, lumina (US) introduced the TruSight Software Suite, which allows sample-to-report analysis for the diagnosis of genetic diseases, offers a comprehensive solution, and gives insightful data through simpler genomic sequencing.
• The market for metagenomic sequencing will see significant growth as sophisticated NGS solutions built on big data analytics and cloud computing are developed for managing, saving, and retrieving the massive amounts of data produced.

Segments Insights

Product and Services Insights

The reagents and consumables segment dominated the market in 2025. This is due to growing demand for sample preparation kits, extraction kits, library preparation reagents, sequencing reagents, and quality control reagents that play a vital role in sequencing processes. While instruments are single-use products, reagents and consumables are required for each sequence and thus create constant sources of revenue for vendors.

The services segment is expected to grow at the fastest rate during the forecast period. This growth is driven by the growing complexity of sequencing projects and the demand for specialized expertise in data analysis and bioinformatics. As research institutions and healthcare organizations demand tailored services to navigate these challenges, the services segment is expected to grow over the forecast period.

Technology Insights

The worldwide market for metagenomics sequencing is divided into four categories based on technology: metatranscriptomics, whole genome sequencing and de novo assembly, and shotgun metagenomics sequencing. Due to the benefits that shotgun sequencing offers over other sequencing techniques, the rise in the number of metagenomics sequencing-based research activities, and healthcare professionals, it is anticipated that the shotgun metagenomics sequencing segment will grow at the fastest rate during the analysis period.

The worldwide metagenomics sequencing market is expected to grow as more people choose to implement shotgun sequencing due to the better benefits provided. Shotgun metagenomic sequencing has seen a rise in use over the past few years as a result of an application that allows for the reading of all the genomes contained within a DNA molecule.

Shotgun metagenomics sequencing dominated the market and is expected to grow during the forecast period, driven by its ability to offer a holistic view of the microbial ecosystem. Shotgun metagenomics enables the comprehensive sampling of all genes in all organisms present in a given complex sample. One of the most precious advantages of shotgun metagenomics is its ability to offer functional insights into microbial communities. The technique is versatile and can be applied to a wide range of sample types, including water, soil, human gut, and more. This makes it a valuable tool for environmental monitoring, clinical diagnostics, and biotechnological applications.

Application Insights

The ecological and environmental metagenomics, clinical diagnosis, drug development, biofuel, and industrial application segments make up the worldwide metagenomics sequencing market, In 2025. However, due to the advancement of tools and software used in metagenomics research, the clinical diagnostics sector is anticipated to expand at the greatest rate from the forecast period. The prevalence of viral and pathogenic diseases has increased, creating opportunities for the worldwide metagenomics sequencing industry to expand.

Additionally, the rising incidence of infectious diseases the need for rapid and accurate diagnostics, and Growing awareness and adoption of precision medicine approaches for personalized treatment foster the growth of clinical diagnostics applications. Furthermore, Growing concerns about environmental pollution and climate change, and Advances in sequencing technologies and bioinformatics tools for studying complex microbial ecosystems drive the growth of ecological and environmental metagenomic applications. Moreover, the growth of this segment is also attributed to increasing demand for new, effective as well as natural product-based drugs to treat various diseases and conditions.

The drug discovery segment held the largest share of the market in 2025. Metagenomic sequencing technology aids in finding bioactive molecules and novel drug targets, which is expected to drive demand for drug discovery. By offering quick and comprehensive genetic data, metagenomic sequencing significantly boosts various stages of the drug discovery process, from target identification to clinical trials, ultimately minimizing the time and cost associated with bringing new drugs to market.

The clinical diagnostics segment is anticipated to grow at the fastest rate during the predicted timeframe. This is due to the growing incidence of infectious diseases, the need for rapid and accurate diagnostics, and increasing awareness and adoption of precision medicine approaches for personalized treatment. Growing use of metagenomic sequencing for infectious disease detection and antimicrobial resistance profiling is improving precision medicine.

Regional Insights

What is the U.S. Metagenomic Sequencing Market Size?

The United States represents the largest share of the metagenomic sequencing market in North America. The growth is driven by strong genomic research infrastructure, advanced sequencing facilities and strong investment in biotechnology. The metagenomics used for microbiome research, infectious disease investigation, and drug discovery. The strong collaboration between research institutions, pharmaceutical and biotechnology companies encourages market development. The presence of key players such as Thermo Fisher Scientific, Pacific Biosciences and Illumina further supports market growth.

The U.S. metagenomic sequencing market size was exhibited at USD 1,090 million in 2025 and is projected to be worth around USD 6,100 million by 2035, growing at a CAGR of 18.79% from 2026 to 2035.

The market for worldwide metagenomics sequencing is currently dominated by North America, and this trend is anticipated to continue throughout the projection period. The North American region generated more than 42.14% of the revenue share in 2025. This is explained by the fact that more metagenomics apps in this area are implementing DNA sequencing. Additionally, this region's supremacy has been aided by the quick implementation of novel sequencing technologies there.

Growth of the market is fueled by an increase in product clearance, product launches, and acquisitions by major companies operating in North America. Additionally, the presence of key market players and government support for genomics research is expected to drive the growth of the market in this region. The European region is expected to witness substantial growth in the metagenomic sequencing market due to the increasing demand for genomic research and development, and the presence of key market players.

The Asia Pacific region is expected to witness rapid growth in the metagenomic sequencing market due to the presence of a large patient population and increasing investments in healthcare infrastructure.

China Market Trends

China dominated the regional metagenomic sequencing market because of large-scale government investments in genomics, strong biotechnology infrastructure and the presence of leading sequencing companies. The country's precision medicine initiatives and massive genomic database projects are accelerating the adoption of metagenomic sequencing. Growing focus on antimicrobial resistance research and pandemic preparedness is increasing the demand for advanced sequencing technologies.

Which Factors Influence the Fastest Growth of the Asia Pacific Market?

Asia Pacific is expected to grow at the fastest CAGR in the metagenomic sequencing market during the forecast period. The growth is driven by the presence of a large patient population and increasing investments in healthcare infrastructure. Countries such as China, Japan, India, and South Korea are developing sequencing capabilities for clinical research, food safety and drug discovery. The government in the region is supporting research and development, promoting initiatives to develop novel technology. The growing demand for personalised healthcare is also encouraging wider use of metagenomic technologies.

Germany Metagenomic Sequencing Market Trends

Germany has experienced the highest growth rate in the last few years, driven by increasing investment in biotechnology and expanding clinical genomics programs in that country. National investments in genomic research, precision medicine, and environmental monitoring are driving demand for kits, reagents, and sequencing-related services, with the market forecasted to expand at double-digit compound annual growth rates through the end of the decade.

Latin America: Center of Agricultural and Research Genomics:

Growing investment in university research, infectious disease control, and agricultural genomics fuels growth in this region. Improved access to sequencing services will also foster research on biodiversity and microbiomes in this region. Increased use of metagenomic approaches in infectious disease diagnostics, microbiome research, environmental monitoring, and agricultural biotechnology is broadening applications and attracting investment.

Brazil Metagenomic Sequencing Market Trends

Brazil is experiencing the fastest growth rate because of large amounts of funding from public health programs for genomics and environmental research. Strategic collaborations between global technology providers and local research centers are enhancing capacity and helping build bioinformatics expertise to handle complex data outputs.

Middle East & Africa: Genomic Infrastructure Expansion

Countries in the Middle East and Africa are starting to adopt metagenomic sequencing technology through various government-led healthcare modernization initiatives and infectious disease surveillance programs, especially in urban research centres. The UAE is rapidly emerging as a key genomics hub in the Middle East and Africa, supported by several strategic investments in precision medicine initiatives.

Saudi Arabia Market Trends

Saudi Arabia represents the leading market within the Middle East and Africa metagenomic sequencing market in 2025, supported by increasing healthcare investment under Vision 2030 and infrastructure development. Government backed genomics initiatives, including the Saudi Human Genome Program, have strengthened national capabilities in sequencing and genetic research. Growing demand for personalised treatments is further encouraging the development of next generation sequencing utilization. The growing collaborations with international biotechnology companies are further supporting market expansion.

Metagenomic Sequencing Market Value Chain Analysis

• Reagents & Sample Preparation Technology: While upstream genes (the products of upstream gene manufacturers) don't produce DNA, they usually supply the components of the downstream process.
  Key Players: QIAGEN (reagents, enzymes, kits) and Illumina (libraries).
• Instrumentation & Bioinformatics Integration: Midstream genes (the instruments used in the midstream process) convert raw materials (e.g., DNA) into usable information (e.g., sequence data).
  Key Players: Oxford Nanopore, Pacific Biosciences, and BGI Genomics.
• Data Interpretation, Clinical Utility & Commercial Services: This chain segment includes the interpretation of sequencing results and report generation, as well as clinical and agricultural uses.
  Key Players: CosmosID, Eurofins Scientific, and Novogene.

Competitive Landscape

The global metagenomic sequencing market is highly competitive and innovation-driven. The major biotechnology and genomics companies are focusing on advanced sequencing technologies, AI-powered bioinformatics and precision medicine applications. The major market players include Illumina, Thermo Fisher Scientific, BGI Genomics, Pacific Biosciences and Oxford Nanopore Technologies. These leading players are investing heavily in research collaborations, high-throughput sequencing platforms and cloud-based genomic data analysis solutions to strengthen their market position.

These companies are involved in strategic partnerships between research institutes, pharmaceutical companies and sequencing providers, accelerating technological advancements and product commercialization. Companies are also expanding their presence in clinical diagnostics, microbiome research, infectious disease surveillance and agricultural genomics to achieve growing demand.

Top Companies in the Metagenomic Sequencing Market and Their Offerings

• Illumina, Inc - A United States based company recognised for developing next generation sequencing.
  • Key offerings - NovaSeq X Series and MiSeq/NextSeq systems, Illumina Connected Analytics and BaseSpace platforms.
• Thermo Fisher Scientific Inc. - A United States based company that provides integrated solutions covering the entire metagenomic pipeline.
  • Key offerings - Ion Torrent Genexus System
• Oxford Nanopore Technologies plc - A United Kingdom based company develops distinctive sequencing approach based on nanopore technology.
  • Key offerings - MinION, PromethION, and EPI2ME software.
• Pacific Biosciences of California, Inc. (PacBio) - The company focuses on highly accurate, single molecule long read technology.
  • Key offerings - Revio and Sequel IIe sequencing systems
• QIAGEN N.V. - A Netherlands based company provides dedicated metagenomics solutions covering sample preparation, library preparation and data analysis.
  • Key offerings - DNeasy PowerSoil, PowerMax isolation kits and QIAGEN CLC Genomics Workbench
• BGI Group (BGI Genomics) - A China based genomics organization with extensive experience in large-scale sequencing and genomic research.
  • Key offerings - DNBSEQ-T7 and Shotgun Metagenomic Sequencing services

Metagenomic Sequencing Market Companies

• BGI Group
• DNAStar, Inc.
• Eurofins Scientific
• GENEWIZ
• Illumina, Inc.
• IntegraGen SA
• Macrogen, Inc.
• Microsynth AG
• Novogene Corporation
• NuGEN Technologies, Inc.
• Oxford Nanopore Technologies Ltd.
• PerkinElmer
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Zymo Research Corporation

Recent Developments

• In May 2026. MGI Tech announced the deployment of its RNA Pathogen Metagenomic Sequencing Solution and its CycloneSEQ Comprehensive Metagenomic Sequencing Solution, in response to the recent outbreak of Andes Hantavirus. Leveraging MGI's unique SEQ ALL matrix advantage, these solutions offer a complete technical chain for quick diagnosis, outbreak tracking, and prevention decision-making.
• In January 2026, Illumina introduced Illumina Connected Multiomics, a cloud-based software platform designed to simplify large-scale genomic and multiomic data analysis. The platform supports integration of genomics, transcriptomics, proteomics and epigenetics data, helping researchers improve metagenomic sequencing workflows and microbiome analysis capabilities. (Source: https://investor.illumina.com)
• In March 2026, Oxford Nanopore Technologies partnered with A.D.A.M. Innovations in Japan to accelerate advanced genomic sequencing applications and precision medicine development. The collaboration focuses on expanding comprehensive nanopore sequencing technologies in clinical and research settings. (Source: https://finance.yahoo.com/ )
• In May 2026, Oxford Nanopore Technologies revealed new advancements in microbial sequencing, transcriptomics and high-output sequencing workflows during its London Calling conference. The company introduces improvements in DNA, RNA and epigenetic sequencing capabilities along with faster microbial profiling solutions. (Source: https://www.ipgroupplc.com)
• In March 2019, Illumina and the Lundbeck Foundation GeoGenetics Centre (Denmark) collaborated to build one of the most comprehensive databases of ancient genomes. The study of the genetic origins of particular mental and neurological disorders and infectious microbes will also be aided by this cooperation.
• Using Illumina's NGS technology, KingMed Diagnostics (China) and Illumina worked together to create cancer and hereditary disease diagnostic apps in January 2019.

Segments Covered in the Report

By Product and Services

• Reagents and consumables
• Tools
• Services

By Technology

• Shotgun Metagenomics Sequencing
• 16S rRNA Sequencing
• Whole Genome Sequencing & De Novo Assembly
• Metatranscriptomics

By Application

• Ecological & Environmental Metagenomics
• Clinical Diagnostics
• Drug Discovery
• Biofuel
• Industrial Applications

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa